Structure Therapeutics (GPCR) Income from Continuing Operations (2022 - 2026)

Structure Therapeutics' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 75968000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 62.21% year-over-year to 75968000.0; the TTM figure through Mar 2026 stood at 25558000.0 (up 15.47% YoY), while the FY2025 annual figure was 3577000.0, up 137.9% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 75968000.0, down from 177783000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 177783000.0 in Q4 2025, with the low at 75968000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 23280000.0 (2023), against an average of 5786588.24.
• Peak annual rise in Income from Continuing Operations reached 132.06% in 2025, while the deepest fall reached 136.85% in 2025.
• Structure Therapeutics' Income from Continuing Operations stood at 32323000.0 in 2022, then soared by 72.31% to 55696000.0 in 2023, then soared by 37.55% to 76610000.0 in 2024, then soared by 132.06% to 177783000.0 in 2025, then slumped by 142.73% to 75968000.0 in 2026.
• Business Quant data shows GPCR's Income from Continuing Operations at 75968000.0 in Q1 2026, 177783000.0 in Q4 2025, and 65712000.0 in Q3 2025.